The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Gilteritinib (Xospata) for Acute Myeloid Leukemia
(Final Recommendation Issued as of May 20, 2020)
Atezolizumab (Tecentriq) & Bevacizumab (Avastin) for Hepatocellular Carcinoma
(Open for Input on Submission until June 4, 2020)
Sonidegib (Odomzo) for Basal Cell Carcinoma
(Pending Submission as of May 15, 2020)
Nivolumab (Opdivo) in combo with Ipilimumab (Yervoy) for Non-Small Cell Lung Cancer
(Pending Submission as of May 26, 2020)